Drugs / 89Zr-DFO-girentuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07179770 | Sep 2025 → Sep 2027 expected | clear cell renal carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179770 ↗ |
| Modality | Diagnostic / imaging agent | “imaging CAIX expression with 89Zr-DFO-girentuximab PET” NCT07179770 ↗ |
| Route | Intravenous | “10 mg single slow intravenous (IV) administration” NCT07179770 ↗ |